[go: up one dir, main page]

MX2007013301A - Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos. - Google Patents

Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos.

Info

Publication number
MX2007013301A
MX2007013301A MX2007013301A MX2007013301A MX2007013301A MX 2007013301 A MX2007013301 A MX 2007013301A MX 2007013301 A MX2007013301 A MX 2007013301A MX 2007013301 A MX2007013301 A MX 2007013301A MX 2007013301 A MX2007013301 A MX 2007013301A
Authority
MX
Mexico
Prior art keywords
abnormalities
sugar
therapeutic agent
lipid metabolism
prophylactic
Prior art date
Application number
MX2007013301A
Other languages
English (en)
Inventor
Yuji Abe
Aki Kusunoki
Hayashi Yoshiharu
Akahoshi Fumihiko
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of MX2007013301A publication Critical patent/MX2007013301A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una preparacion farmaceutica para el tratamiento y/o prevencion de anormalidades del metabolismo de la azucar/lipidos en la sangre asociados con las comodas, para los cuales todavia no se encuentra un metodo terapeutico o un agente terapeutico satisfactorios.
MX2007013301A 2005-04-26 2006-04-26 Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos. MX2007013301A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005127523 2005-04-26
JP2006008695 2006-04-26

Publications (1)

Publication Number Publication Date
MX2007013301A true MX2007013301A (es) 2008-03-07

Family

ID=37307926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007013301A MX2007013301A (es) 2005-04-26 2006-04-26 Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos.

Country Status (12)

Country Link
US (2) US20090088442A1 (es)
EP (1) EP1882474B1 (es)
JP (1) JP5100375B2 (es)
KR (1) KR101333876B1 (es)
CN (1) CN101175494B (es)
AT (1) ATE486604T1 (es)
BR (1) BRPI0607680A2 (es)
CA (1) CA2605847C (es)
DE (1) DE602006017997D1 (es)
ES (1) ES2355156T3 (es)
MX (1) MX2007013301A (es)
WO (1) WO2006118127A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2602259A3 (en) 2005-02-18 2014-09-10 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
NZ604091A (en) 2008-08-15 2014-08-29 Boehringer Ingelheim Int Purin derivatives for use in the treatment of fab-related diseases
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
AR075204A1 (es) 2009-01-29 2011-03-16 Boehringer Ingelheim Int Inhibidores de dpp-4 y composiciones farmaceuticas que los comprenden, utiles para tratar enfermedades metabolicas en pacientes pediatricos, particularmente diabetes mellitus tipo 2
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
PH12012501037A1 (en) 2009-11-27 2013-01-14 Boehringer Ingelheim Int Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin
US9572806B2 (en) * 2009-12-18 2017-02-21 Mitsubishi Tanabe Pharma Corporation Elution-stabilized preparation
JP2013522279A (ja) 2010-03-18 2013-06-13 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病及び関連状態の治療で用いるｇｐｒ１１９作動薬とｄｄｐ−ｉｖ阻害薬リナグリプチンの組合せ
CA2797310C (en) 2010-05-05 2020-03-31 Boehringer Ingelheim International Gmbh Glp-1 receptor agonist and dpp-4 inhibitor combination therapy
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (de) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
US20020006899A1 (en) * 1998-10-06 2002-01-17 Pospisilik Andrew J. Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals
DE60140708D1 (de) * 2000-08-10 2010-01-14 Mitsubishi Tanabe Pharma Corp Prolinderivative und deren Verwendung als Medikamente
US20040180925A1 (en) * 2000-12-27 2004-09-16 Kenji Matsuno Dipeptidylpeptidase-IV inhibitor
BR0206831A (pt) * 2001-02-02 2004-07-06 Takeda Chemical Industries Ltd Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
US6727261B2 (en) 2001-12-27 2004-04-27 Hoffman-La Roche Inc. Pyrido[2,1-A]Isoquinoline derivatives
AU2003232405A1 (en) * 2002-06-04 2003-12-19 Pfizer Products Inc. Flourinated cyclic amides as dipeptidyl peptidase iv inhibitors
US6710040B1 (en) * 2002-06-04 2004-03-23 Pfizer Inc. Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors
US6995183B2 (en) * 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
EP2602259A3 (en) * 2005-02-18 2014-09-10 Mitsubishi Tanabe Pharma Corporation Salt of proline derivative, solvate thereof, and production method thereof

Also Published As

Publication number Publication date
CN101175494B (zh) 2011-07-13
EP1882474A1 (en) 2008-01-30
ES2355156T3 (es) 2011-03-23
ATE486604T1 (de) 2010-11-15
CN101175494A (zh) 2008-05-07
WO2006118127A1 (ja) 2006-11-09
EP1882474A4 (en) 2008-07-09
CA2605847C (en) 2014-02-04
CA2605847A1 (en) 2006-11-09
KR20080010436A (ko) 2008-01-30
DE602006017997D1 (de) 2010-12-16
US20090088442A1 (en) 2009-04-02
JP5100375B2 (ja) 2012-12-19
BRPI0607680A2 (pt) 2009-09-22
EP1882474B1 (en) 2010-11-03
US20100305139A1 (en) 2010-12-02
JPWO2006118127A1 (ja) 2008-12-18
KR101333876B1 (ko) 2013-11-27

Similar Documents

Publication Publication Date Title
WO2007002927A3 (en) Imaging geometry
WO2006066008A3 (en) Device and methods for identifying and treating aspirin non-responsive patients
WO2007146426A3 (en) Nanoshells for drug delivery
IL196745A (en) Idabanon for use in providing mucosal pathways to treat disease
ZA200901826B (en) Treating pain, diabetes, and lipid metabolism disorders
WO2007112403A3 (en) Prevention and treatment of ischemia-reperfusion injury
WO2009002867A3 (en) Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
EP2036574A4 (en) MEDICAL AGENT FOR THE TREATMENT OF FAT, DIABETES AND DISEASES IN CONNECTION WITH IMPROVED GLUCOSE TOLERANCE
ZA200807879B (en) Use of bifidobacterium longum for the prevention and treatment of inflammation
EP1758595A4 (en) Use of lipid conjugates in the treatment of diseases
WO2011018501A3 (en) Composition including an unsaponifiable fraction
WO2007002572A3 (en) Nattokinase for reducing whole blood viscosity
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
MX2007013301A (es) Agente profilactico/terapeutico para la anormalidades del metabolismo del azucar/lipidos.
WO2006112716A3 (en) Nutritional supplement for hiv patients
WO2006003123A3 (en) Radionuclides for medical use
PL1965797T3 (pl) Zmniejszenie zawrotów głowy, efektu ubocznego związanego z terapią pirfenidonem
WO2008016640A3 (en) Use of poloxamer for the prevention and/or treatment of heart failure
EP2112902A4 (en) METHOD AND MEANS FOR MEASURING THE SYSTOLIC BLOOD PRESSURE IN THE FOOT CONTROL
WO2007038768A3 (en) Method for lowering blood pressure in pre-hypertensive individuals and/or individuals with metabolic syndrome
WO2007023154A3 (de) EISEN(III)-KOMPLEXVERBINDtMGEN ZUR BEHANDLUNG VON EISENMANGEL-ZUSTÄNDEN BEI PATIENTEN MIT CHRONISCH-ENTZÜNDLICHER DARMERKRANKUNG
WO2007018588A8 (en) Stable pharmaceutical composition comprising linezolid form iv
IL191365A0 (en) A preparation for use in the case of diseases of the metabolism of blood, including diabetes
PL2193789T3 (pl) Zastosowanie 5-metylo-1,3-benzenodiolu lub jego pochodnych w przygotowaniu leku i funkcjonalnej żywności do leczenia lub zapobiegania depresji
WO2007097922A3 (en) Receptor-based blood detoxification system

Legal Events

Date Code Title Description
FG Grant or registration